Virtu Financial LLC Purchases New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Virtu Financial LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 20,024 shares of the medical equipment provider’s stock, valued at approximately $1,801,000.

Several other large investors have also recently added to or reduced their stakes in ZBH. AMG National Trust Bank boosted its holdings in Zimmer Biomet by 29.1% in the 3rd quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock valued at $4,960,000 after purchasing an additional 11,339 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in shares of Zimmer Biomet by 47.5% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 62,079 shares of the medical equipment provider’s stock worth $6,115,000 after purchasing an additional 19,996 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Zimmer Biomet by 6.1% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock worth $39,383,000 after purchasing an additional 22,992 shares during the period. Inceptionr LLC bought a new position in shares of Zimmer Biomet during the third quarter worth approximately $1,217,000. Finally, Wilsey Asset Management Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $32,439,000. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.28% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Robert W. Baird set a $92.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a report on Wednesday, April 29th. Citigroup cut their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Finally, Truist Financial reissued a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Stock Up 0.2%

Shares of NYSE ZBH opened at $88.13 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company has a market cap of $17.05 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 2.59 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The stock has a 50-day moving average price of $87.24 and a two-hundred day moving average price of $90.13.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.